STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 98 filers reported holding STEMLINE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 2.58 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $342,000 | -50.1% | 22,300 | -58.2% | 0.00% | -50.0% |
Q1 2019 | $686,000 | +29.9% | 53,400 | -4.0% | 0.00% | +100.0% |
Q4 2018 | $528,000 | -68.5% | 55,600 | -44.9% | 0.00% | -75.0% |
Q3 2018 | $1,675,000 | +6.1% | 100,900 | +2.6% | 0.00% | 0.0% |
Q2 2018 | $1,578,000 | – | 98,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |